PE22798A1 - Inhibidor de proteina quinasa c - Google Patents

Inhibidor de proteina quinasa c

Info

Publication number
PE22798A1
PE22798A1 PE1996000829A PE00082996A PE22798A1 PE 22798 A1 PE22798 A1 PE 22798A1 PE 1996000829 A PE1996000829 A PE 1996000829A PE 00082996 A PE00082996 A PE 00082996A PE 22798 A1 PE22798 A1 PE 22798A1
Authority
PE
Peru
Prior art keywords
inhibitor
methanosulphonic
protein kinase
salt
oxadiazaciclohexadecin
Prior art date
Application number
PE1996000829A
Other languages
English (en)
Inventor
Nagy Alphonse Farid
Michael Robert Jirousek
Leonard Larry Winneroski Jr
Margaret Mary Faul
Gary Lowell Engel
Lori Ann Richardson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE22798A1 publication Critical patent/PE22798A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

SE REFIERE A LA SAL DE FORMULA (Ia), Y SUS ENANTIOMEROS, SOLVATOS E HIDRATOS (PREFERENTEMENTE MONOHIDRATOS) Y AL PROCEDIMIENTO DE PREPARACION DE (Ia), QUE COMPRENDE: HACER REACCIONAR (S)-13-[(DIMETILAMINO)METIL]-10,11,14,15-TETRAHIDRO 4,9:16,21-DEMETENO-1H,13H-DIBENZO[e,k]PIRROLO[3,4-H] [1,4,13]OXADIAZACICLOHEXADECIN-1,3(2H)-DIONA CON ACIDO METANOSULFONICO, EN PRESENCIA DE UN DISOLVENTE ORGANICO NO REACTIVO, TAL COMO: ACETONA/AGUA EN UNA PROPORCION EN VOLUMEN DE 5:1 A 10:1. ESTA SAL METANOSULFONICA PRESENTA UNA BIODISPONIBILIDAD Y SOLUBILIDAD MEJORADA, SIENDO USADO PREFERENTEMENTE EN EL TRATAMIENTO DE LA DIABETES MELLITUS
PE1996000829A 1995-11-20 1996-11-18 Inhibidor de proteina quinasa c PE22798A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US697095P 1995-11-20 1995-11-20

Publications (1)

Publication Number Publication Date
PE22798A1 true PE22798A1 (es) 1998-05-11

Family

ID=21723527

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1996000829A PE22798A1 (es) 1995-11-20 1996-11-18 Inhibidor de proteina quinasa c

Country Status (34)

Country Link
US (3) US5710145A (es)
EP (1) EP0776895B1 (es)
JP (1) JP3348859B2 (es)
KR (1) KR100304210B1 (es)
CN (1) CN1093759C (es)
AR (2) AR004717A1 (es)
AT (1) ATE172199T1 (es)
AU (1) AU711125B2 (es)
BR (1) BR9611724A (es)
CA (1) CA2237221C (es)
CO (1) CO4750823A1 (es)
CY (1) CY2103B1 (es)
CZ (1) CZ297524B6 (es)
DE (1) DE69600784T2 (es)
DK (1) DK0776895T3 (es)
EA (1) EA000967B1 (es)
EG (1) EG23871A (es)
ES (1) ES2122764T3 (es)
HU (1) HU226821B1 (es)
IL (1) IL124417A (es)
MX (1) MX9803792A (es)
MY (1) MY118068A (es)
NO (1) NO310196B1 (es)
NZ (1) NZ323571A (es)
PE (1) PE22798A1 (es)
PL (1) PL184715B1 (es)
RO (1) RO120074B1 (es)
SI (1) SI0776895T1 (es)
TR (1) TR199800759T2 (es)
TW (1) TW403754B (es)
UA (1) UA61897C2 (es)
WO (1) WO1997018809A1 (es)
YU (1) YU49315B (es)
ZA (1) ZA969646B (es)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5624949A (en) * 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
US6093740A (en) * 1997-04-30 2000-07-25 Eli Lilly And Company Therapeutic treatment for skin disorders
AR017200A1 (es) 1997-12-23 2001-08-22 Astrazeneca Ab Compuestos inhibidores de la proteina cinasa c, sales farmaceuticamente aceptables de los mismos, formulaciones farmaceuitcas que los comprenden, usode las mismas y proceso para la sintesis de dichos compuestos
US6620977B1 (en) 1998-01-30 2003-09-16 Daiso Co., Ltd. Process for producing butanetriol derivative
US6291446B1 (en) 1998-03-05 2001-09-18 Eli Lilly And Company Therapeutic treatment for cytomegalovirus infection
US6225301B1 (en) 1998-03-05 2001-05-01 Eli Lilly And Company Therapeutic treatment for renal dysfunction
US6103713A (en) * 1998-03-05 2000-08-15 Eli Lilly And Company Therapeutic treatment for autoimmune diseases
US6103712A (en) * 1998-03-05 2000-08-15 Eli Lilly And Company Therapeutic treatment for asthma
AU758241B2 (en) * 1998-03-13 2003-03-20 University Of British Columbia, The Granulatimide derivatives for use in cancer treatment
SE9800835D0 (sv) 1998-03-13 1998-03-13 Astra Ab New Compounds
CA2245029A1 (en) 1998-03-13 1999-09-13 University Of British Columbia Granulatimide compounds as g2 checkpoint inhibitors
US6706721B1 (en) 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
US6127401A (en) 1998-06-05 2000-10-03 Cephalon, Inc. Bridged indenopyrrolocarbazoles
TWI223598B (en) * 1998-06-22 2004-11-11 Pfizer Ireland Pharmaceuticals An intranasal pharmaceutical composition for the treatment of male erectile dysfunction or female sexual disorders, an intranasal delivery system or device and sildenafil mesylate
GB9828640D0 (en) * 1998-12-23 1999-02-17 Smithkline Beecham Plc Novel method and compounds
US6841567B1 (en) * 1999-02-12 2005-01-11 Cephalon, Inc. Cyclic substituted fused pyrrolocarbazoles and isoindolones
US6492406B1 (en) 1999-05-21 2002-12-10 Astrazeneca Ab Pharmaceutically active compounds
US6284783B1 (en) 1999-06-09 2001-09-04 The Uab Research Foundation Use of bisindolylmaleimide compounds to induce Fas-mediated apoptosis
US6399780B1 (en) 1999-08-20 2002-06-04 Cephalon, Inc. Isomeric fused pyrrolocarbazoles and isoindolones
UA74803C2 (uk) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
US7087613B2 (en) * 1999-11-11 2006-08-08 Osi Pharmaceuticals, Inc. Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
US6852688B2 (en) 2000-03-10 2005-02-08 University Of Florida Compositions for treating diabetic retinopathy and methods of using same
CA2413156C (en) * 2000-07-03 2009-08-18 Gala Design, Inc. Expression vectors
US20030224415A1 (en) * 2001-06-29 2003-12-04 Gala Design, Inc. Selection free growth of host cells containing multiple integrating vectors
AU2001271614B2 (en) 2000-07-03 2007-05-31 Catalent Pharma Solutions, Llc Host cells containing multiple integrating vectors
US6300106B1 (en) * 2000-11-22 2001-10-09 Ppg Industries Ohio, Inc. Method of preparing 3-[2-{(Methylsulfonyl)oxy}-ethoxy ]-4-(triphenylmethoxy)-1-butanol, methane sulfonate
US7384738B2 (en) * 2002-03-28 2008-06-10 Bremel Robert D Retrovirus-based genomic screening
US20040038304A1 (en) * 2002-03-28 2004-02-26 Gala Design, Inc. Antibody libraries
US20030232741A1 (en) * 2002-05-06 2003-12-18 Washington University Methods of treatment of glaucoma and other conditions mediated by NOS-2 expression via inhibition of the EGFR pathway
DE10244453A1 (de) * 2002-09-24 2004-04-01 Phenomiques Gmbh Hemmung der Proteinkinase C-alpha zur Behandlung von Krankheiten
US7232842B2 (en) * 2003-01-10 2007-06-19 Board Of Trustees Of The Leland Stanford Junior University Kinase inhibitors and associated pharmaceutical compositions and methods of use
US7521420B2 (en) 2003-06-18 2009-04-21 Tranzyme Pharma, Inc. Macrocyclic antagonists of the motilin receptor
US20050152942A1 (en) * 2003-12-23 2005-07-14 Medtronic Vascular, Inc. Medical devices to treat or inhibit restenosis
US20050221429A1 (en) * 2004-01-16 2005-10-06 Cardinal Health Pts, Llc Host cells containing multiple integrating vectors comprising an amplifiable marker
NZ550340A (en) * 2004-03-17 2010-08-27 Lars Michael Larsen Prevention of retinopathy by inhibition of the visual cycle using a retinoid
DE102004019413A1 (de) * 2004-04-19 2005-11-24 Phenos Gmbh Hemmung der Proteinkinase C epsilon zur Behandlung von Krankheiten
WO2006071451A2 (en) * 2004-12-03 2006-07-06 The Regents Of The University Of California Compounds that prevent macrophage apoptosis and uses thereof
US20070281988A1 (en) * 2004-12-20 2007-12-06 Cameron Norman E Combination Therapy for Vascular Complications Associated with Hyperglycemia
US8034823B2 (en) * 2005-02-22 2011-10-11 Savvipharm Inc Method of increasing drug oral bioavailability and compositions of less toxic orotate salts
GB0504203D0 (en) * 2005-03-01 2005-04-06 Novartis Ag Organic compounds
US8158586B2 (en) * 2005-04-11 2012-04-17 Pharmagap Inc. Inhibitors of protein kinases and uses thereof
WO2008027619A2 (en) 2006-09-01 2008-03-06 Intermec Ip Corp. Rfid tag system with block coding, such as space-time block coding
PE20091522A1 (es) * 2007-12-21 2009-10-29 Novartis Ag Composicion farmaceutica solida que contiene 3-(1.h-indol-3-il)-4-[2-(4-metil-piperazin-1-il)-quinazolin-4-il]-quinazolin-4-il]-pirrol-2,5-diona
EP2181999A1 (en) 2008-11-03 2010-05-05 Zentiva, A.S. Method of manufacturing ruboxistarin
US9265764B2 (en) * 2009-02-27 2016-02-23 Massachusetts Institute Of Technology Uses of chemicals to modulate GSK-3 signaling for treatment of bipolar disorder and other brain disorders
MX2012011341A (es) 2010-03-30 2012-11-12 Novartis Ag Inhibidores de pkc para el tratamiento de linfoma de celulas-b que tenga señalizacion activa cronica de receptores de celulas-b.
UA115250C2 (uk) 2012-11-29 2017-10-10 Новартіс Аг Фармацевтичні комбінації
WO2014174478A1 (en) 2013-04-26 2014-10-30 Novartis Ag Pharmaceutical combinations of a pkc inhibitor and a c-met receptor tyrosine kinase inhibitor
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
US20180185259A1 (en) 2016-12-19 2018-07-05 Chromaderm, Inc. Methods of treating hyperpigmentation disorders
EP3600440A1 (en) 2017-03-20 2020-02-05 Sienna Biopharmaceuticals, Inc. Reduced exposure conjugates modulating therapeutic targets
WO2018175302A1 (en) 2017-03-20 2018-09-27 Sienna Biopharmaceuticals, Inc. Polymer conjugates targeting c-src with reduced exposure
EP3658142B1 (en) 2017-07-28 2024-04-17 Applied Therapeutics, Inc. Compositions and methods for treating galactosemia
KR20230005944A (ko) 2020-05-01 2023-01-10 어플라이드 테라퓨틱스 인크. 소르비톨 데히드로게나제 결핍 치료를 위한 알도스 리덕타제 억제제
KR20230128175A (ko) * 2022-02-25 2023-09-04 주식회사 온코크로스 루복시스타우린을 포함하는 항암용 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ227850A (en) * 1988-02-10 1991-11-26 Hoffmann La Roche Indole substituted pyrrole derivatives; preparatory process and medicaments for use against inflammatory immunological, bronchopulmonary or vascular disorders
US5292747A (en) * 1990-08-07 1994-03-08 Hoffman-La Roche Inc. Substituted pyrroles
AU5100393A (en) * 1992-09-25 1994-04-26 Schering Corporation Diindolo compounds and pharmaceutical compositions containing them
US5624949A (en) * 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
CA2137203C (en) * 1993-12-07 2006-11-28 William Francis Heath Jr. Protein kinase c inhibitors

Also Published As

Publication number Publication date
PL326754A1 (en) 1998-10-26
HU226821B1 (en) 2009-11-30
CA2237221C (en) 2003-03-25
CA2237221A1 (en) 1997-05-29
YU60996A (sh) 1999-03-04
TR199800759T2 (xx) 2001-01-22
EG23871A (en) 2007-11-27
EA199800374A1 (ru) 1998-10-29
MX9803792A (es) 1998-09-30
DE69600784T2 (de) 1999-04-08
JPH11500149A (ja) 1999-01-06
NO982182L (no) 1998-05-13
AU711125B2 (en) 1999-10-07
SI0776895T1 (en) 1999-04-30
CN1202825A (zh) 1998-12-23
US5710145A (en) 1998-01-20
RO120074B1 (ro) 2005-08-30
CZ297524B6 (cs) 2007-01-03
CO4750823A1 (es) 1999-03-31
CZ150298A3 (cs) 1998-12-16
KR19990067596A (ko) 1999-08-25
AU1054897A (en) 1997-06-11
IL124417A0 (en) 1998-12-06
US6117861A (en) 2000-09-12
CY2103B1 (en) 2002-04-05
DK0776895T3 (da) 1999-06-23
DE69600784D1 (de) 1998-11-19
JP3348859B2 (ja) 2002-11-20
KR100304210B1 (ko) 2001-11-05
YU49315B (sh) 2005-06-10
IL124417A (en) 2002-11-10
HUP9903377A3 (en) 2000-04-28
TW403754B (en) 2000-09-01
PL184715B1 (pl) 2002-12-31
HUP9903377A2 (hu) 2000-02-28
AR004717A1 (es) 1999-03-10
ATE172199T1 (de) 1998-10-15
NO310196B1 (no) 2001-06-05
WO1997018809A1 (en) 1997-05-29
MY118068A (en) 2004-08-30
AR004336A1 (es) 1998-11-04
EP0776895B1 (en) 1998-10-14
ZA969646B (en) 1998-05-18
ES2122764T3 (es) 1998-12-16
NO982182D0 (no) 1998-05-13
CN1093759C (zh) 2002-11-06
NZ323571A (en) 1998-12-23
EA000967B1 (ru) 2000-08-28
EP0776895A1 (en) 1997-06-04
US6015807A (en) 2000-01-18
UA61897C2 (en) 2003-12-15
BR9611724A (pt) 1999-06-01

Similar Documents

Publication Publication Date Title
PE22798A1 (es) Inhibidor de proteina quinasa c
ES2167720T3 (es) Compuestos de 1-fenilpirazol y aplicaciones medicinales de los mismos.
ZA200300889B (en) Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of hyperuricemia.
FI956020A (fi) Pysyvä vesiformulaatio ja sen käyttö
MXPA03009411A (es) COMPOSICIoN FARMACeUTICA SUMINISTRABLE ORALMENTE QUE COMPRENDE UN MEDICAMENTO DE POCA HIDROSUBILIDAD (INHIBIDOR DE COX-2), UN SOLVENTE, UN ACIDO GRASO Y UNA AMINA ORGANICA.
ES2175760T3 (es) Dispersiones acuosas que contienen pliuretanos con grupos carbodiimida.
MXPA02005806A (es) Agente de contraste fluorescente cercano al infrarrojo y formacion de imagen fluorescente.
ES2166093T3 (es) Procedimiento para la preparacion de compuestos de pirimidina.
IL157669A0 (en) Nitrogen-based camptothecin derivatives
ES2086407T3 (es) Estructura de una carcasa inflable.
ES2170318T3 (es) Derivados de 10,13,15-trioxatriciclo(9.2.1.1.9.6)-pentadecanona, procedimiento para su preparacion y medicamentos que contienen estos compuestos.
LV10360A (lv) Pesticidu sastavi tablesu veida
KR930700502A (ko) 6-아미노옥타히드로인돌리진트리올 유도체
BR0307008A (pt) N-aril-4,5-dia-minopirazóis e agentes de tingimento que contêm esses compostos
IT1317031B1 (it) Procedimento migliorato per la preparazione di (e,z)3-(2-amminoetossimmino)-androstano-6, 17-dione e di suoi analoghi.
SV1999000075A (es) Derivados de 3-(2-oxo-[1,3']bipirrolidinil-3-ilidenemetil)-cefemos
IS2198B (is) Nýstárleg ferli, er fela í sér valmöguleika á rúmafstöðu atóma og atómhópa, til að smíða gabapentín-hliðstæður
DK0408437T3 (da) 2-Alkyliminobenzothiazolinderivater, fremgangsmåder til deres fremstilling og lægemidler indeholdende disse forbindelser
DE69413803D1 (de) Verfahren zur herstellung von diazomethanderivaten
DK1109782T3 (da) Fremgangsmåde til fremstilling af N-beskyttede azetidin-2-carboxylsyrer (AzeOH'er)
DE68910931D1 (de) Verfahren zur Herstellung von Propionsäurederivaten.
HUP0201574A2 (en) Process for the preparation of fumagillin
DE50002107D1 (de) Alpha-liponsäure(-derivate)enthaltende retardform
ATE93845T1 (de) Verfahren zur herstellung von 4,4'-bis-(4aminophenoxy)-diphenylsulfon.
HU9302786D0 (en) New thiophene-2-carboxylic acid derivatives and process for preparing them

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed